MRK241220C96000
- 5.81
- -0.44-7.04%
Merck & Co Newsroom
Merck announced the termination of the development of two experimental anticancer drugs.
On December 17, Gelonghui reported that Merck announced on Monday that it has halted the development of the experimental cancer drugs vibostolimab and favezelimab after multiple trials failed when combined with the best-selling drug Keytruda to treat various cancers. Marjorie Green, head of Global Clinical Development Oncology at Merck Research, stated: "After careful analysis of the data, we have decided to stop the development of these candidate drugs to prioritize other ongoing projects."
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion
Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab
Express News | Merck Provides Update on Keyvibe and Keyform Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab
Dow's 115-Point Rally Highlighted By Gains In Honeywell, Nike Shares
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
Merck's KEYTRUDA Approved in Combination With Chemotherapy in China to Treat Lung Cancer
Express News | Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Merck & Co. Gets Key European Backing for Welireg in Two Uses
Express News | Merck: Final Decision Is Expected in Q1 of 2025
Express News | Merck Receives Positive EU Chmp Opinion for Welireg® (Belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
Express News | EMA's Chmp: Recommended Granting Conditional Marketing Authorisation for Welireg (Belzutifan)